References of "Jerusalem, Guy"
     in
Bookmark and Share    
Full Text
See detailA miRNA expression based diagnostic tool for breast cancer using random forests
Wenric, Stéphane ULg; Freres, Pierre ULg; Josse, Claire ULg et al

Poster (2013, December 09)

We developed a novel diagnostic tool for breast cancer using circulating miRNA expression levels as features of a supervised machine learning problem. We showed very good results on an independent ... [more ▼]

We developed a novel diagnostic tool for breast cancer using circulating miRNA expression levels as features of a supervised machine learning problem. We showed very good results on an independent validation cohort. [less ▲]

Detailed reference viewed: 32 (8 ULg)
See detailStudy of the pro-tumoral effects of MT4-MMP
Yip, Cassandre ULg; PAYE, Alexandra ULg; Truong, Alice ULg et al

Scientific conference (2013, December 05)

Detailed reference viewed: 16 (5 ULg)
Full Text
Peer Reviewed
See detailBOLERO-3 : Everolimus plus Trastuzumab and Vinorelbine in asian patients with HER2-positive metastatic breast cancer
Toi, Masakazu; Masuda, Norikazu; ANDRE, Fabrice et al

Poster (2013, December)

Detailed reference viewed: 21 (5 ULg)
Full Text
Peer Reviewed
See detailmTOR inhibitors in advanced breast cancer: ready for prime time?
Martin, Lesley-Ann; Andre, Fabrice; Campone, Mario et al

in Cancer Treatment Reviews (2013), 39(7), 742-52

Current therapeutic approaches for advanced breast cancer frequently target receptors mediating cell survival and proliferation, such as the estrogen receptor and/or progesterone receptor and human ... [more ▼]

Current therapeutic approaches for advanced breast cancer frequently target receptors mediating cell survival and proliferation, such as the estrogen receptor and/or progesterone receptor and human epidermal growth factor receptor-2. Although these approaches are effective for many patients, treatment resistance is common. Therefore, new treatment approaches are needed for patients with advanced breast cancer. Mammalian target of rapamycin is a highly conserved serine-threonine kinase that acts as a major signaling hub that integrates and synergizes with cellular proliferation, survival, and/or motility signals mediated by estrogen receptor, human epidermal growth factor receptor-2, and other receptor tyrosine kinases. Dysregulation of mammalian target of rapamycin signaling occurs in various tumor types, including breast cancer, and has been associated with cancer pathogenesis, disease progression, and treatment resistance. Recent clinical trials show that combined inhibition of mammalian target of rapamycin and estrogen receptor represents an effective strategy for treating hormone receptor-positive advanced breast cancer progressing on nonsteroidal aromatase inhibitor therapy, and data from ongoing trials combining mammalian target of rapamycin inhibition with human epidermal growth factor receptor-2-targeted therapy are awaited. This review focuses on the molecular rationale underlying strategies to enhance sensitivity to treatment in hormone receptor-positive and human epidermal growth factor receptor-2-positive advanced breast cancer, the clinical efficacy of such approaches, and future perspectives. [less ▲]

Detailed reference viewed: 44 (4 ULg)
See detailStudy of the pro-tumoral effects of MT4-MMP
Yip, Cassandre ULg; PAYE, Alexandra ULg; Truong, Alice ULg et al

Scientific conference (2013, September 13)

Detailed reference viewed: 14 (2 ULg)
Full Text
Peer Reviewed
See detailEvaluation of Everolimus (EVE) in HER2+ advanced breast cancer (BC) with activated PI3K/mTOR pathway : exploratory biomarker observations from the BOLERO-3 trial
JERUSALEM, Guy ULg; ANDRE, Fabrice; CHEN, David et al

in European Journal of Cancer (2013, September), 49(Supplement 3), 8

Detailed reference viewed: 49 (14 ULg)
See detailRegulation of breast cancer cell properties by MT4-MMP
Yip, Cassandre ULg; PAYE, Alexandra ULg; Truong, Alice ULg et al

Scientific conference (2013, July 02)

Detailed reference viewed: 16 (3 ULg)
See detailRegulation of breast cancer cell properties by MT4-MMP
Yip, Cassandre ULg; PAYE, Alexandra ULg; Truong, Alice ULg et al

Scientific conference (2013, May 17)

Detailed reference viewed: 12 (5 ULg)
Full Text
See detailExome sequencing of tumors: relevance in copy-number alteration (CNA) analysis and fixed tissue samples.
Wenric, Stéphane ULg; JOSSE, Claire ULg; Fasquelle, Corinne ULg et al

Poster (2013, March 15)

Genomic DNA has been extracted from both cryopreserved and formalin-fixed paraffin-embedded forms of 2 different tumor samples (triple negative, and Her2+). Exome sequencing has been performed on all 4 ... [more ▼]

Genomic DNA has been extracted from both cryopreserved and formalin-fixed paraffin-embedded forms of 2 different tumor samples (triple negative, and Her2+). Exome sequencing has been performed on all 4 forms, as well as SNP and CNA detection. A comparison of the various metrics and results related to the sequencing, mapping, and variants detection has been done, outlining what can, and can’t be done with exome data sequenced from cryopreserved and FFPE tissue. [less ▲]

Detailed reference viewed: 26 (6 ULg)
Full Text
Peer Reviewed
See detailThe 2006 adjuvant Trastuzumab convention in Belgium: 5 years later
Vanderhaegen, J; Paridaens, R; Piccart, M et al

Poster (2013, March)

Detailed reference viewed: 10 (1 ULg)
Full Text
Peer Reviewed
See detailEverolimus Plus Exemestane Versus Everolimus or Capecitabine Monotherapy in Breast Cancer : BOLERO-6
Ejlertsen, Bent; JERUSALEM, Guy ULg; Hurvitz, Sara et al

Poster (2013, March)

The data from this trial will provide insight into the safety and efficacy of the combination of EVE and EXE versus EVE or capecitabine monotherapy in women with ER+, HER2- ABC progressing on/after prior ... [more ▼]

The data from this trial will provide insight into the safety and efficacy of the combination of EVE and EXE versus EVE or capecitabine monotherapy in women with ER+, HER2- ABC progressing on/after prior LET or ANA. [less ▲]

Detailed reference viewed: 91 (1 ULg)
See detailRegulation of breast cancer cell properties by MT4-MMP
Yip, Cassandre ULg; PAYE, Alexandra ULg; Truong, Alice ULg et al

Scientific conference (2013, January 29)

Detailed reference viewed: 17 (5 ULg)
See detailRegulation of breast cancer cell properties by MT4-MMP
Yip, Cassandre ULg; PAYE, Alexandra ULg; Truong, Alice ULg et al

Scientific conference (2013, January 28)

Detailed reference viewed: 14 (2 ULg)
Full Text
Peer Reviewed
See detailLe cas clinique du mois. Metastase musculaire en presence d'un cancer de l'ovaire.
Benoit, A.; Jerusalem, Guy ULg; GENNIGENS, Christine ULg

in Revue medicale de Liege (2013), 68(11), 557-61

We report the case of a patient with a sero-papillary ovarian cancer and a pectoral muscle metastasis. Muscular metastases are more common than previously suspected; any physician could encounter this ... [more ▼]

We report the case of a patient with a sero-papillary ovarian cancer and a pectoral muscle metastasis. Muscular metastases are more common than previously suspected; any physician could encounter this type of case in his daily practice. This paper summarizes the literature on the subject. [less ▲]

Detailed reference viewed: 41 (5 ULg)
Full Text
Peer Reviewed
See detailCancer risk in immune-mediated inflammatory diseases (IMID).
Beyaert, Rudi; Beaugerie, Laurent; Van Assche, Gert et al

in Molecular cancer (2013), 12(1), 98

Inflammation and cancer have a profound yet ambiguous relationship. Inflammation - especially chronic inflammation - has protumorigenic effects, but inflammatory cells also mediate an immune response ... [more ▼]

Inflammation and cancer have a profound yet ambiguous relationship. Inflammation - especially chronic inflammation - has protumorigenic effects, but inflammatory cells also mediate an immune response against the tumor and immunosuppression is known to increase the risk for certain tumors.This article reviews current literature on the role of inflammation in cancer and the cancer risk in immune-mediated inflammatory diseases (IMIDs). We discuss the effect on cancer risk of different drug classes used in the treatment of IMIDs treatment, including biologicals such as tumor necrosis factor (TNF) inhibitors.Overall cancer incidence and mortality risk are similar to the general population in inflammatory bowel disease (IBD), and slightly increased for rheumatoid arthritis and psoriasis, with risk profiles differing for different tumor types. Increased risk for non-melanoma skin cancer is associated with thiopurine treatment in IBD, with the combination of anti-TNF and methotrexate in rheumatoid arthritis and with PUVA, cyclosporine and anti-TNF treatment in psoriasis. Data on the safety of using biologic or immunosuppressant therapy in IMID patients with a history of cancer are scarce.This review provides clinicians with a solid background to help them in making decisions about treatment of immune-mediated diseases in patients with a tumor history.This article is related to another review article in Molecular Cancer: http://www.molecular-cancer.com/content/12/1/86. [less ▲]

Detailed reference viewed: 42 (9 ULg)